Introduction: Retinopathy of prematurity (ROP) is an important preventable cause of childhood visual impairment. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has emerged as an alternative or adjunct to laser photocoagulation, particularly for posterior ROP. This study evaluated clinical outcomes of intravitreal aflibercept, alone or in relation to laser treatment, in a university hospital setting.
Methods: This monocentric retrospective cohort study included preterm infants screened for ROP, between January 2023 and June 2025, with at least 24 weeks of post-treatment follow-up. Type 1 ROP was treated according to ETROP criteria with intravitreal aflibercept and/or laser photocoagulation. Treatment characteristics, retreatment, ROP severity, regression time, and complications were analyzed.
Results: Overall, 254 eyes of 127 infants were screened. ROP was diagnosed in 92 eyes of 46 infants (36.2%); 69 eyes (75.1%) regressed spontaneously, while 23 eyes required treatment. Eleven eyes received aflibercept and 12 received primary laser photocoagulation. Aflibercept was predominantly used for zone I and posterior zone II disease. Aflibercept monotherapy was sufficient for at least 24 weeks in 72.8% of treated eyes, while three eyes (27.2%) subsequently required laser. Two laser-treated eyes (16.6%) required aflibercept retreatment. Median regression time was 9 days after aflibercept versus 13 days after laser. No aflibercept-related complications occurred; after laser, one eye developed self-clearing vitreous hemorrhage.
Conclusion: Intravitreal aflibercept was effective, particularly for posterior ROP, with slightly faster regression than laser. Most treated eyes required no retreatment during follow-up. However, long-term surveillance remains essential because persistent avascular retina may predispose to delayed ROP reactivation.

